title: Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Richey
authors.forename: Chaan
authors.initials: C
authors.lastname: Ng
authors.forename: Zita D
authors.initials: ZD
authors.lastname: Lim
authors.forename: Eric
authors.initials: E
authors.lastname: Jonasch
authors.forename: Nizar M
authors.initials: NM
authors.lastname: Tannir
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012074:Remission Induction; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure; D000093542:Gemcitabine
chemical_list: D047428:Protein Kinase Inhibitors; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil; D000093542:Gemcitabine